Cargando…

Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals

Background: Chronic hepatitis C (CHC) is associated with hepatic and extrahepatic complications, including cardiovascular disease (CVD). The effects of sustained virological response (SVR) and liver fibrosis on CVD risk are not well established. Aims: We aim to assess the dynamics of Fibrosis-4 (FIB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramadan, Mohammad Said, Boccia, Filomena, Moretto, Simona Maria, De Gregorio, Fabrizio, Gagliardi, Massimo, Iossa, Domenico, Durante-Mangoni, Emanuele, Zampino, Rosa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572655/ https://www.ncbi.nlm.nih.gov/pubmed/36233646 http://dx.doi.org/10.3390/jcm11195781

Ejemplares similares

Anthropometric parameters and liver histology influence lipid metabolic changes in HCV chronic hepatitis on direct-acting antiviral treatment
por: Iossa, Domenico, et al.
Publicado: (2021)

Guillain-Barré syndrome as clinical presentation of a recently acquired hepatitis C
por: Boccia, Filomena, et al.
Publicado: (2023)

Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review
por: Ramadan, Mohammad Said, et al.
Publicado: (2021)

Infective endocarditis involving MitraClip(©) devices: a systematic literature review
por: Bertolino, Lorenzo, et al.
Publicado: (2023)

Early viral kinetics and response to treatment in a hepatitis C virus genotype 5 infected patient
por: Durante-Mangoni, Emanuele, et al.
Publicado: (2011)

Effects of Direct-Acting Antiviral Agents on the Mental Health of Patients with Chronic Hepatitis C: A Prospective Observational Study
por: Fabrazzo, Michele, et al.
Publicado: (2020)

Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective
por: Ramadan, Mohammad Said, et al.
Publicado: (2021)

Safety and Efficacy of Direct Antiviral Agents for Hepatitis C in Patients with Malignancies Other Than Liver Cancer: A Case Series
por: Patauner, Fabian, et al.
Publicado: (2022)

Incidence, Risk Factors and Clinical Implications of Glucose Metabolic Changes after Heart Transplant
por: Durante-Mangoni, Emanuele, et al.
Publicado: (2022)

Prognostic value of pro-adrenomedullin and copeptin in acute infective endocarditis
por: Zampino, Rosa, et al.
Publicado: (2021)

Risk Factors and Outcome of Multidrug-Resistant Infections after Heart Transplant: A Contemporary Single Center Experience
por: Karruli, Arta, et al.
Publicado: (2021)

Dissecting the correlates of N-terminal prohormone brain natriuretic peptide in acute infective endocarditis
por: Bertolino, Lorenzo, et al.
Publicado: (2022)

Clinical Significance and Prognostic Value of Hemostasis Parameters in 337 Patients with Acute Infective Endocarditis
por: Zampino, Rosa, et al.
Publicado: (2021)

Prognostic Value of Decreased High-Density Lipoprotein Cholesterol Levels in Infective Endocarditis
por: Zampino, Rosa, et al.
Publicado: (2022)

Long-Term Outcome of Infective Endocarditis Involving Cardiac Implantable Electronic Devices: Impact of Comorbidities and Lead Extraction
por: Durante-Mangoni, Emanuele, et al.
Publicado: (2022)

Cardiac complications during the active phase of COVID-19: review of the current evidence
por: Ramadan, Mohammad Said, et al.
Publicado: (2021)

Clinical significance of hyperhomocysteinemia in infective endocarditis: A case–control study
por: Iossa, Domenico, et al.
Publicado: (2016)

Early experience with remdesivir in SARS-CoV-2 pneumonia
por: Durante-Mangoni, Emanuele, et al.
Publicado: (2020)

Liver injury in remdesivir-treated COVID-19 patients
por: Zampino, Rosa, et al.
Publicado: (2020)

Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments?
por: Adinolfi, Luigi Elio, et al.
Publicado: (2018)

Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows
por: Guarino, Maria, et al.
Publicado: (2018)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C
por: Ponziani, Francesca Romana, et al.
Publicado: (2017)

Towards supporting greater and lower cost access to direct acting antiviral treatment for hepatitis C for all patients
por: Al-Busafi, Said A., et al.
Publicado: (2017)

Effect of a Cooperation Strategy between Primary Care Physicians and Hospital Liver Units on HBV Care in Campania, Italy
por: Zampino, Rosa, et al.
Publicado: (2018)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Ultra-long-acting (XLA) antivirals for chronic viral hepatitis
por: Soriano, Vicente, et al.
Publicado: (2022)

A Balancing Act: MDA5 in Antiviral Immunity and Autoinflammation
por: Dias Junior, Antonio Gregorio, et al.
Publicado: (2019)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

The Risk of Hepatocellular Carcinoma After Directly Acting Antivirals for Hepatitis C Virus Treatment in Liver Transplanted Patients: Is It Real?
por: Strazzulla, Alessio, et al.
Publicado: (2016)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
por: Wang, Yadong, et al.
Publicado: (2022)

Direct-acting antivirals for acute hepatitis C in HIV-infected MSM
por: Millard, James Daniel, et al.
Publicado: (2016)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
por: Hill, Andrew, et al.
Publicado: (2018)

Hepatitis C virus infection in children in the era of direct-acting antiviral
por: Pawlowska, Malgorzata, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fufkcshhg8j4ll1num96n6ec98